Brief: Arbutus Presents Preliminary AB-729 And Pegylated Interferon Alfa-2A Combination Data At EASL Congress 2023
21/06/2023 07:05
June 21 (Reuters) - Arbutus Biopharma Corp ABUS.O :
* ARBUTUS PRESENTS PRELIMINARY AB-729 AND PEGYLATED
INTERFERON
ALFA-2A COMBINATION DATA AT EASL CONGRESS 2023
* ARBUTUS BIOPHARMA CORP SAYS TREATMENT WAS GENERALLY WELL
TOLERATED WITH CONTINUED HBSAG DECLINES IN SOME PATIENTS
Source text for Eikon: ID:nGNX1W2szY
Further company coverage: ABUS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arbutus Biopharma
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
Arbutus rises after FDA lifts clinical hold for experimental hepatitis B drug
Brief: Arbutus Announces Final Results Of Its Us$230 Million Modified “Dutch Auction” Tender Offer
Brief: Arbutus Announces Preliminary Results Of Its Us$230 Million Modified “Dutch Auction” Tender Offer
U.S. STOCKS ON THE MOVE-Moderna, O-I Glass, Aveanna Healthcare